TORONTO, ON / ACCESSWIRE / May 14, 2019 / GeneNews Limited (TSX: GEN) (“GeneNews” or the “Company”), a life sciences company specializing in blood-based biomarker tests for early cancer detection, has announced that Gary the Prostate, their national spokesperson for prostate cancer awareness has been recently diagnosed with an elevated PSA.
According to Gary, “Like many men who are told they have an elevated PSA, I was concerned about prostate cancer, but I was also worried about how a prostate biopsy might affect me.”
While Prostate Specific Antigen (PSA) is currently the most used screening test for prostate cancer, it is widely recognized that PSA results can indicate the possibility of prostate cancer when none is present.
Fortunately, Gary advocated for himself and learned about a new test for prostate cancer called the Prostate Health Index (phi). The Prostate Health Index is an FDA approved blood test that can help differentiate prostate cancer from benign prostate conditions in men with elevated PSA.1
Gary and his doctor used the Prostate Health Index to determine the probability of having prostate cancer. Since Gary’s phi score was low, he didn’t require a prostate biopsy. Gary is now in active surveillance with his urologist and may be retested with phi at a later date.
“Gary’s story is not an unusual one,” says GeneNews Chairman and CEO, James Howard-Tripp. “In fact, 70% of men with an elevated PSA who have a biopsy do not have cancer.2“
The Prostate Health Index utilizes three different PSA markers (PSA, freePSA, and p2PSA) as part of a sophisticated algorithm to more reliably determine the probability of cancer in patients with elevated PSA levels and can help men and their physicians decide if a prostate biopsy is indicated.3 The Prostate Health Index is included in the National Comprehensive Cancer Network (NCCN) Guideline for Prostate Cancer Early Detection as a blood test to improve specificity for prostate cancer detection.4
The Prostate Health Index is indicated for men age 50 years and older with an elevated PSA between 4ng/ml and 10ng/ml.5
Patients can now initiate a physician order for the Prostate Health Index at http://www.mycancerrisk.info/phi.html.
Learn More About Gary’s Story at http://www.mycancerrisk.info/garypsa.html.
- Loeb S, Sanda MG, Broyles DL, et al. The Prostate Health Index Selectively Identifies Clinically Significant Prostate Cancer. The Journal of Urology. 2015;193(4):1163-11692.
- Biddle C, Brasel A, Underwood W 3rd, et al. Experiences of Uncertainty in Men With an Elevated PSA. Am J Mens Health. 2016;11(1):24-34.
- White J, Shenoy V, Tutrone RF, et al. Clinical utility of the Prostate Health Index (phi) for biopsy decision management in a large group urology practice setting. Prostate Cancer and Prostatic Diseases. 2018; 21: 78-84.
- National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Prostate Cancer Early Detection.
- Beckman Coulter Access Hybritech p2PSA Instructions for Use.
GeneNews is dedicated to developing and commercializing innovative solutions for early cancer detection. Our mission is to provide advanced diagnostics that can help physicians identify cancer in their patients at the earliest possible stage (Stage 0) when it is the most curable. As early pioneers in the liquid biopsy space, GeneNews developed one of the first blood-based biomarker tests for the early identification of Colorectal Cancer. ColonSentry® uses the company’s proprietary Sentinel Principle technology which is based on the scientific observation that circulating blood reflects, in a detectable way, what is occurring throughout the body. Today, more than 100,000 patients in the U.S. have benefited from the ColonSentry test. GeneNews’ next generation test, Aristotle®, will use this proven technology to test for ten cancers from a single blood sample. In addition to building a pipeline of products for early cancer detection, GeneNews operates a CAP accredited and CLIA certified, clinical reference laboratory based in Richmond, Virginia that offers the ColonSentry® test as well as licensed biomarker tests for lung, breast and prostate cancers. www.GeneNews.com.
James R. Howard-Tripp
Chairman & CEO
Tel. (905) 209-2030
Financial Communication Advisor
Tel. (514) 815-8799
SOURCE: GeneNews Limited
View source version on accesswire.com: